The effect of a sulfonylurea, glibenclamide, on the release of insulin, glucagon, and somatostatin was studied in the isolated perfused rat pancreas. At glucose concentrations of 1.1 mM or less, the drug stimulated somatostatin release, whereas glucagon release, after 2-3 min of increase, was markedly inhibited. Insulin release was moderately stimulated, and maximal release occurred relatively late. A moderate glucose load (6.7 mM) inhibited glibenclamide-induced release of somatostatin, whereas the two in combination exerted an additive action on insulin release. Greater ,ug/ml was added to the infusion medium (Fig. 1) . Before the addition of glibenclamide, the amount of insulin and somatostatin in the perfusate increased with increasing glucose concentrations, whereas the amount of glucagon decreased (Fig.   1 ).
which has an important role in the kinetics of insulin and glucagon release induced by sulfonylureas. Sulfonylurea compounds stimulate the release of insulin and somatostatin from the pancreas (1) (2) (3) . Their effect on insulin release is dependent upon the prevailing glucose concentration (4, 5) . There are contradictory reports regarding the effect of sulfonylureas on glucagon release: they have been considered to either stimulate (6) or inhibit this function (2, 7, 8) .
The present study demonstrates that the effect of one such sulfonylurea, glibenclamide, on somatostatin and glucagon release is glucose dependent as well and suggests a paracrine action of somatostatin on the alpha and beta cells of the islets.
MATERIAL AND METHODS
The pancreas was removed from fasting (18 hr) Sprague ,ug/ml was added to the infusion medium ( Fig. 1) . Before the addition of glibenclamide, the amount of insulin and somatostatin in the perfusate increased with increasing glucose concentrations, whereas the amount of glucagon decreased ( Fig.   1 ).
The insulin release by glibenclamide was considerably more pronounced at glucose concentrations of 3.3 and 4.4 mM than 0-and 1.1 mM. In contrast, the release of somatostatin after glibenclamide addition was more pronounced at glucose concentrations of 0-3.3 mM than at 4.4 mM.
The elevated levels of glucagon appearing at glucose concentrations of 0 and 1.1 mM were markedly inhibited by gli- benclamide. This latter effect become apparent 4-5 min after the glibenclamide infusion was started. In addition, glibenclamide seemed to exert a stimulatory effect on glucagon release during the first 2 min. Effect of Glibenclamide on Release of Insulin and Somatostatin with Increasing Glucose Loads. In these experiments, the pancreas was equilibrated for 20 min with 3.3 mM glucose and then stimulated with increasing amounts of glucose in the absence or presence of glibenclamide (Fig. 2, Table 1 ). The lowest glucose load applied, 6.7 mM, clearly stimulated insulin relepse. This was even more pronounced with 16.7 mM glucose, whereas infusion of 33.3 mM glucose was accompanied by only a minor further increase. Somatostatin release was not affected by 6.7 mM glucose whereas glucose at 16.7 and 33.3 mM was stimulatory.
Infusion of 1 gg of glibenclamide per ml with 6.7 mM glucose produced an additive effect on insulin release. The drug had no effect on the insulin release stimulated by'16.7 and 33.3 mM glucose.
The increase in somatostatin release by glibenclamide was markedly inhibited by 6.7 mM glucose (P < 0.005). The inhibition was less pronounced at 16.7 mM glucose (P > 0.05) and almost absent at 33.3 mM glucose (P > 0.05) ( Table 1) .
This complex interaction between glucose concentration, glibenclamide, and the release of insulin and somatostatin was confirmed by another series of experiments (Fig. 3) . Again, glibenclamide enhanced the insulmiogenic effect of 6.7 mM but not of 16.7 mM glucose. Furthermore, 6.7 mM glucose itself had no effect on somatostatin release but markedly inhibited glibenclamide-induced release of somatostatin. Conversely, 16 
DISCUSSION
The insulin-releasing effect of the sulfonylureas is well recognized. The present study demonstrates that one such drug, glibenclamide, also influences the release of two other islet hormones, glucagon and somatostatin, and that the prevailing glucose concentration is of importance in this connection.
As expected, glibenclamide was a more potent insulin releaser under normoglycemic than under hypoglycemic conditions. Somatostatin release also increased with increasing glucose concentrations, but the response of somatostatin to glibenclamide was lowest at the highest basal glucose concentration.
The effect of glibenclamide on glucagon release at the two lowest glucose concentrations occurred in two phases: an initial stimulation lasting for about 3 min followed by marked inhibition. This observation probably explains previous reports suggesting either a stimulatory or inhibitory effect of sulfonylureas on glucagon release (6) (7) (8) . The inhibition of glucagon release by glibenclamide, which was parallel to the phase of rapid increase in somatostatin release, implies that somatostatin may have mediated the inhibition of glucagon release. In such a case, the only possible explanation is a paracrine action of somatostatin on the glucagon-producing (alpha) cells of the islets. This is supported by our finding that glibenclamide (3) (15, 16) . It thus appears that sulfonylureas (glibenclamide) stimulate the alpha and beta as well as delta cells of the pancreas and that the prevailing glucose concentration plays an important role in the action of the drug on the three cell types. The studies also imply that a paracrine interaction of somatostatin with the alpha and beta cells is important in determining the net effect of the drug on insulin and glucagon release.
So far, it cannot be concluded that similar interrelationships among the islet cells also exist in humans. However, the development of a drug that, by stimulating somatostatin release, inhibits the release of glucagon in humans is not unlikely. Such a drug would be of value in the treatment of insulin-requiring diabetics. Another possibility implicit in these results is the development of drugs that stimulate pancreatic insulin release without interfering with somatostatin release. Such a drug, in principle, could be of value in the treatment of non-insulinrequiring diabetics.
